20 February 2025
After publishing three guidelines in 2024, for Sjögren disease, systemic sclerosis and Behçets, 2025 promises to be even more of a bumper year for new and updated clinical guidelines. Take a look below at what’s coming up.
March 2025
- NEW: Foot health in inflammatory arthritis
Foot problems are almost universal in people with inflammatory arthritis so this brand new guideline is highly anticipated. This is a whole life-course guideline and it will cover foot problems in a number of different rheumatic conditions, including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and juvenile idiopathic arthritis.
April 2025
- UPDATE: Treatment of axial spondyloarthritis
Since the previous 2015 guideline, pharmacological management has advanced considerably to incorporate new classes of biologic DMARDs (including biosimilars), targeted synthetic DMARDs and treatment strategies such as drug tapering. Look out for a jam-packed session at our annual conference in April featuring all the latest evidence for management of axSpA included in this updated guideline.
July 2025
- OVERVIEW: Management recommendations for ANCA-associated vasculitis (AAV)
These recommendations are being developed by comparing other international society recommendations and updating the evidence review for UK practice. They will offer systematic and evidence-based recommendations to support UK clinicians in the management of AAV across the whole life course. Our public consultation for the draft recommendations has just launched and your feedback is welcomed.
Autumn 2025
- EXPANDED: Management and treatment for systemic lupus erythematosus (SLE)
There have been rapid advances in the diagnosis, assessment, and therapeutic management of SLE since the previous guideline in 2017. This update will demonstrate a major expansion to take a whole life course approach, from childhood to adulthood, for the first time. General approaches to management as well as organ-specific treatment, including lupus nephritis and cutaneous lupus, will be covered.
- EXPANDED: Conventional synthetic DMARDs
Also expanded to people of all ages, this update will be introduced at our annual conference in April. You can expect to see the addition of voclosporin; new evidence-based recommendations for pre-screening and monitoring liver toxicity with MTX, including considering a role for fibroscans; updated guidelines on the frequency of DMARD monitoring; updated recommendations concerning patient education, vaccinations and considerations for comorbid conditions and updated guidelines on hydroxychloroquine retinopathy screening.
GET INVOLVED
Would you like to support our clinical guideline development by joining a future guideline working group? Complete this short form to express an interest. ---
--
Access our guidelines